



April 21, 2026

bioMérieux SA
% Stéphanie Millon-Serme
Regulatory Affairs Specialist
bioMérieux SA
376 Chemin De L'Orme
Marcy-L'Etoile, 69280
France

Re: K260447

Trade/Device Name: ETEST Gepotidacin (GEP) (0.016-256 µg/mL)
Regulation Number: 21 CFR 866.1640
Regulation Name: Antimicrobial susceptibility test powder
Regulatory Class: Class II
Product Code: JWY
Dated: February 11, 2026
Received: February 11, 2026

Dear Stéphanie Millon-Serme:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

FDA's substantial equivalence determination also included the review and clearance of your Predetermined Change Control Plan (PCCP). Under section 515C(b)(1) of the Act, a new premarket notification is not required for a change to a device cleared under section 510(k) of the Act, if such change is consistent with an established PCCP granted pursuant to section 515C(b)(2) of the Act. Under 21 CFR 807.81(a)(3), a new premarket notification is required if there is a major change or modification in the intended use of a device, or if there is a change or modification in a device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process. Accordingly, if deviations from the established PCCP result in a major change or modification in the intended use of the device, or result in a change or modification in the device that could significantly affect the safety or effectiveness of the device, then a new premarket notification would be required consistent with section 515C(b)(1) of the Act and 21 CFR 807.81(a)(3). Failure to submit such a premarket submission would constitute adulteration and misbranding under sections 501(f)(1)(B) and 502(o) of the Act, respectively.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (<https://www.fda.gov/media/99812/download>) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (<https://www.fda.gov/media/99785/download>).

Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these

requirements, please see the UDI System webpage at <https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system>.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,


Noel J. Gerald -S

Noel J. Gerald, Ph.D.
Deputy Director
Division of Microbiology Devices
OHT7: Office of In Vitro Diagnostics
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)
K260447

Device Name
E TEST Gepotidacin (GEP) (0.016-256 µg/mL)

Indications for Use (Describe)

E TEST is a manual, quantitative technique for the determination of antimicrobial susceptibility of non-fastidious Gram-negative and Gram-positive aerobic bacteria and fastidious bacteria. The system comprises a predefined antibiotic gradient which is used to determine the Minimum Inhibitory Concentration (MIC, in µg/mL) of different antimicrobial agents against microorganisms tested on agar media after overnight incubation.

Testing with E TEST Gepotidacin (GEP) (0.016-256 µg/mL) is indicated for Enterobacterales, Staphylococcus saprophyticus, Enterococcus faecalis and Neisseria gonorrhoeae, as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC).

E TEST Gepotidacin (GEP) (0.016-256 µg/mL) demonstrated acceptable performance with the following microorganisms:

- Escherichia coli
- Staphylococcus saprophyticus
- Enterococcus faecalis
- Neisseria gonorrhoeae

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.


This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."



ETEST® Gepotidacin (GEP) (0.016-256 µg/mL)

A. 510(k) Submission Information:

Submitter's Name: bioMerieux SA
Address: 376 Chemin de l'Orme
69280 Marcy-l'Etoile, FRANCE
Contact Person: Stéphanie MILLON-SERME
Regulatory Affairs Specialist
Phone Number: (314) 731-8666
Date of Preparation: February 6th, 2026

B. Device Name:

Formal/Trade Name: **ETEST® Gepotidacin (GEP) (0.016-256 µg/mL)**
Classification Name: 21 CFR 866.1640
Manual Antimicrobial Susceptibility Test Systems
Product Code: JWY
Common Name(s): ETEST® Gepotidacin (GEP)

C. Predicate Device: ETEST® Fosfomicin (FO) (0.032-512 µg/mL) (K210757)



D. Device Description:

ETEST® is a thin, inert and non-porous plastic strip carrying the MIC reading scale in µg/mL on one side and a predefined antibiotic gradient on the other side.

When the strip is applied to an inoculated agar surface, the preformed antibiotic gradient immediately transfers into the agar matrix, then forming a stable, continuous and exponential gradient of antibiotic concentrations directly underneath the strip. Bacterial growth becomes visible during incubation, and a symmetrical inhibition ellipse centered along the strip appears. The MIC value is read from the scale in terms of µg/mL at complete inhibition of bacterial growth, where the pointed end of the ellipse intersects the strip.

ETEST® Gepotidacin (GEP) (0.016-256 µg/mL) contains a range of Gepotidacin from (0.016-256 µg/mL).


E. Intended Use:

ETEST® is a manual, quantitative technique for the determination of antimicrobial susceptibility of non-fastidious Gram-negative and Gram-positive aerobic bacteria and fastidious bacteria. The system comprises a predefined antibiotic gradient which is used to determine the Minimum Inhibitory Concentration (MIC, in µg/mL) of different antimicrobial agents against microorganisms tested on agar media after overnight incubation.

Testing with ETEST® Gepotidacin (GEP) (0.016-256 µg/mL) is indicated for *Enterobacterales*, *Staphylococcus saprophyticus*, *Enterococcus faecalis* and *Neisseria gonorrhoeae*, as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC).

ETEST® Gepotidacin (GEP) (0.016-256 µg/mL) demonstrated acceptable performance with the following microorganisms:

- *Escherichia coli*
- *Staphylococcus saprophyticus*
- *Enterococcus faecalis*
- *Neisseria gonorrhoeae*




F. Summary of the technological characteristics of the new device in comparison to those of the predicate device.

A summary of the similarities and differences of important features of the device and predicate are provided in the table below:

Table 1 - Similarities and Differences of Important Features of the Device and Predicate

Item	Device	Predicate
	ETEST® Gepotidacin (GEP) (0.016-256 µg/mL)	ETEST® Fosfomycin (FO) (0.032-512 µg/mL) (K210757)
General Device Characteristics Similarities		
Intended Use	ETEST® is a manual, quantitative technique for the determination of antimicrobial susceptibility of non-fastidious Gram-negative and Gram-positive aerobic bacteria and fastidious bacteria. The system comprises a predefined antibiotic gradient which is used to determine the Minimum Inhibitory Concentration (MIC, in µg/mL) of different antimicrobial agents against microorganisms tested on agar media after overnight incubation.	ETEST® is a manual, quantitative technique for the determination of antimicrobial susceptibility of non-fastidious Gram-negative and Gram-positive aerobic bacteria and fastidious bacteria. The system comprises a predefined antibiotic gradient which is used to determine the Minimum Inhibitory Concentration (MIC, in µg/mL) of different antimicrobial agents against microorganisms tested on agar media after overnight incubation.
Test Methodology	Quantitative antimicrobial susceptibility test to determine the in vitro susceptibility of microorganisms	Same
Inoculum	Suspension of organism	Same
Type of test	Quantitative	Same
Clinical & Challenge Performance Data	Essential Agreement & Category Agreement (overall species) <i>E. coli</i> , <i>Staphylococcus saprophyticus</i> , <i>Enterococcus faecalis</i> : EA = 97.3% CA = 99.8%	Essential Agreement & Category Agreement (overall species) <i>E. coli</i> EA = 90.8% CA = 99.2%



Item	Device	Predicate
	ETEST® Gepotidacin (GEP) (0.016-256 µg/mL)	ETEST® Fosfomycin (FO) (0.032-512 µg/mL) (K210757)
	<i>Neisseria gonorrhoeae</i> : EA = 96.0% CA = 99.3%	<i>E. faecalis</i> EA = 97.9% CA = 93.7%
Reproducibility	<i>E. coli</i> , <i>Staphylococcus saprophyticus</i> , <i>Enterococcus faecalis</i> : Best case = 100% Worst case = 100 % <i>Neisseria gonorrhoeae</i> : Best case = 100% Worst case = 100 %	Best-case: 98.1% Worst-case: 98.1%
Quality Control	within the expected QC results range >95% of the time	within the expected QC results range >95% of the time
Meets Guidance Document Performance Requirements	Yes	Yes
Differences		
Antimicrobial Agent	Gepotidacin	Fosfomycin
Concentrations	ETEST® Gepotidacin (GEP) (0.016-256 µg/mL)	ETEST® Fosfomycin (FO) (0.032-512 µg/mL) (K210757)
Indicated organisms	Testing with ETEST® Gepotidacin (GEP) (0.016-256 µg/mL) is indicated for <i>Enterobacterales</i> , <i>Staphylococcus saprophyticus</i> , <i>Enterococcus faecalis</i> and <i>Neisseria gonorrhoeae</i> , as recognized by the FDA Susceptibility Test Interpretive Criteria (STIC). ETEST® Gepotidacin (GEP) (0.016-256 µg/mL) demonstrated acceptable performance with the following microorganisms:	Fosfomycin has been shown to be active against the Gram-positive and Gram-negative aerobic microorganisms listed below according to the FDA label for this antimicrobial agent. ETEST® FO can be used to determine the MIC of Fosfomycin against the following microorganisms: Active both <i>in vitro</i> and in clinical infections: • <i>Escherichia coli</i>



Item	Device	Predicate
	ETEST® Gepotidacin (GEP) (0.016-256 µg/mL)	ETEST® Fosfomycin (FO) (0.032-512 µg/mL) (K210757)
	<ul style="list-style-type: none"> • <i>Escherichia coli</i> • <i>Staphylococcus saprophyticus</i> • <i>Enterococcus faecalis</i> • <i>Neisseria gonorrhoeae</i> 	<ul style="list-style-type: none"> • <i>Enterococcus faecalis</i>
Breakpoints	<p><i>E. coli</i> S ≤ 16 I = 32 R ≥ 64</p> <p><i>E. faecalis</i>: S ≤ 4 I = - R = -</p> <p><i>Staphylococcus saprophyticus</i> S ≤ 0.25 I = - R = -</p> <p><i>Neisseria gonorrhoeae</i> S ≤ 1 I = 2 R ≥ 4</p>	<p><i>E. coli</i> (UTI only)* S ≤ 64 I = 128 R ≥ 256</p> <p><i>E. faecalis</i> (UTI only)*: S ≤ 64 I = 128 R ≥ 256</p> <p>* Urinary Tract Infection only</p>



G. Performance Overview

ETEST® Gepotidacin (GEP) (0.016-256 µg/mL) demonstrated substantially equivalent performance when compared with the CLSI M07 12th Ed; (March, 2024) broth microdilution reference method, following rules as defined in the FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA, issued on August 28, 2009-and following specifications as defined in CLSI M100 35th Ed. (January 2025).

This Premarket Notification (510[k]) presents data in support of **ETEST® Gepotidacin (GEP) (0.016-256 µg/mL)**.

External evaluations were conducted with fresh and stock clinical isolates, as well as a set of challenge strains. The external evaluations were designed to establish the performance of **ETEST® Gepotidacin (GEP) (0.016-256 µg/mL)** by comparing with the CLSI broth microdilution reference method.

ETEST® Gepotidacin (GEP) (0.016-256 µg/mL) demonstrated acceptable performance as presented in the table below:


Table 2- Performance Characteristics for ETEST® Gepotidacin (GEP) (0.016-256 µg/mL)

Organisms	Strains (N)	% Essential Agreement (EA)^{a)}	% Category Agreement (CA)
<i>Escherichia coli</i> b)	383	96.6	99.7
<i>Staphylococcus saprophyticus</i> b)	110	99.1	100
<i>Enterococcus faecalis</i> b)	110	98.2	100
<i>Neisseria gonorrhoeae</i> b)	300	96.0	99.3

Notes:

a) EA = % of MIC values within ± 1 dilution of the reference method.

b) Testing with the optional ETEST® tools was not evaluated during the ETEST® Gepotidacin clinical studies.



Limitations

- Due to unacceptable categorical agreement (CA below 90%) and the occurrence of two (2) very major errors (2/11; 18.1%), *Klebsiella pneumoniae* should not be tested with ETEST® Gepotidacin (GEP) (0.016-256 µg/mL) and should be tested using an alternative method.
- The ability of ETEST® Gepotidacin (GEP) (0.016-256 µg/mL) to detect resistance or non-susceptibility with the following organisms is unknown because an insufficient number of resistant or non-susceptible strains were encountered at the time of comparative testing: *Escherichia coli*, *Staphylococcus saprophyticus* and *Enterococcus faecalis*.

Reproducibility and Quality Control demonstrated acceptable results.

Conclusion:

The performance data presented in this submission support a substantial equivalence decision. **ETEST® Gepotidacin (GEP) (0.016-256 µg/mL)** is substantially equivalent to **ETEST® Fosfomicin (FO) (0.032-512 µg/mL) (K210757)**.